Tausif Butt
President presso Idorsia Pharmaceuticals US, Inc.
Posizioni attive di Tausif Butt
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Idorsia Pharmaceuticals US, Inc. | President | 05/09/2023 | - |
Storia della carriera di Tausif Butt
Precedenti posizioni note di Tausif Butt
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CHEMOCENTRYX, INC. | Chief Operating Officer | 24/02/2021 | 20/10/2022 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01/01/2019 | 01/01/2021 |
Formazione di Tausif Butt
| Imperial College London | Graduate Degree |
| University of Brighton | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Regno Unito | 4 |
| Stati Uniti | 3 |
Posizioni
| Chief Operating Officer | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| Aziende private | 2 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
| Idorsia Pharmaceuticals US, Inc. |
- Borsa valori
- Insiders
- Tausif Butt
- Esperienza
